- Details
- Description
MAIWEIJIAN (Denosumab) is a prescription medicine containing denosumab, a monoclonal antibody that inhibits RANKL, a protein involved in the formation and activity of osteoclasts.
Indications: Denosumab is used for the treatment of certain bone-related conditions, including osteoporosis and the prevention of skeletal-related events in patients with certain cancers that have spread to the bones. The approved indication and dosage depend on the specific product and treatment regimen.
Dosage form: Solution for subcutaneous injection.
Administration: Administered by subcutaneous injection according to the dosing schedule prescribed by a healthcare professional.
Possible adverse effects: May include hypocalcemia, infections, skin reactions, and muscle or joint pain. Rare but serious reactions can include osteonecrosis of the jaw and atypical femoral fractures.
Important: Calcium and vitamin D supplementation may be recommended, and calcium levels should be monitored as appropriate. MAIWEIJIAN (Denosumab) should be used under medical supervision.
